General Information

Age Group

Adults

Status

Recruiting

Protocol Number

NCT07166406

Background Information

This study is being done to answer the following question: 

  • Will stereotactic body radiation therapy (SBRT) to the liver combined with immunotherapy 
    extend your life longer than immunotherapy alone?

We are doing this study because we want to find out if this approach is better or worse than the 
usual approach for your liver cancer. The usual approach is defined as care most people get for 
liver cancer.

For more information, visit: https://clinicaltrials.gov/study/NCT07166406

Offered At

8081 Innovation Park Drive
Fairfax, VA 22031
Principal Investigator

Grace Lee, MD

Eligibility Information

  • Diagnosis of HCC by at least 1 criterion listed below: 
    • Pathologically (histologically or cytologically) proven diagnosis of HCC (strongly recommended)
    • Radiographically proven (American Association for the Study of Liver Diseases [AASLD] criteria) diagnosis of HCC by multiphasic MRI and/or CT scan is allowed.
    • For patients with a prior or concurrent malignancy, pathologic confirmation of hepatocellular cancer is required. 
  • Age ≥ 18
  • ECOG Performance Status of 0-2
  • Not Pregnant and Not Nursing

Ineligibility Information

  • No prior systemic therapy or transarterial radioembolization (TARE) for HCC
  • No history of liver transplantation.
  • No medical contraindication to the standard of care immunotherapy
  • No history of allergic reaction to the systemic therapy agent(s), compounds of similar 
    chemical or biologic composition to the systemic therapy agent(s) (or any of its 
    excipients).